CHF Solutions Announces Launch of Ultrafiltration Therapy Using Aquadex FlexFlow® System at Beebe Healthcare
May 15 2019 - 8:30AM
CHF Solutions (Nasdaq: CHFS) today announces that Sussex County,
Delaware-based health system, Beebe Healthcare, has initiated
offering ultrafiltration therapy using the company’s Aquadex
FlexFlow system.
“As heart failure and other conditions that contribute to fluid
overload expand worldwide, CHF continues to provide a proven
solution for managing this patient population to improve their
quality of life and reducing the cost of care,” said John Erb, CEO
of CHF Solutions. “We are proud to be a part of the Beebe
Healthcare system and look forward to partnering with Beebe’s
clinicians in the care of their fluid overloaded patients.”
“This treatment has become a very viable and useful alternative
for appropriate heart failure patients, and we are excited to have
it available at Beebe Healthcare,” said Alberto Rosa, MD, Medical
Director of Heart Failure. “The Aquadex FlexFlow system gives us a
wonderful option for treating patients and keeping them comfortable
when they no longer respond to diuretics.”
Lynn Toth, DNP, MSN, RN, NP-C, Cardiovascular Medical Specialist
added, “There are many potential uses for aquapheresis as the Beebe
program grows, from weekly treatments that allow heart failure
patients to manage their fluid build-up, to fluid removal that
enables patients to undergo surgery.“
Beebe Healthcare serves a rapidly growing community with several
campuses located throughout Sussex County, Delaware. The Margaret
H. Rollins Lewes Campus, is home to the health system’s 210
licensed-bed acute care hospital. In 2019, Beebe opened the Center
for Robotic Surgery, which features multiple specialties. Beebe’s
Rehoboth Health Campus near Rehoboth Beach is home to the Tunnell
Cancer Center as well as several outpatient services. In May 2019,
Beebe will break ground for a Specialty Surgical Hospital on that
campus, which will serve as the regional hub for short-stay
elective surgeries. Beebe also operates outpatient locations in
Georgetown, Millsboro, Milton, and Millville. In 2020, Beebe will
open their South Coastal Health Campus near Millville, which will
feature a freestanding emergency room and second comprehensive
cancer center. Founded in 1916, Beebe Healthcare is a
not-for-profit health system, and many programs and facilities are
made possible by the generous support of the community. Specialty
services include: cardiac and vascular, general and specialty
surgery, oncology, women's health, and orthopedics as well as
ancillary and post-acute services. Additionally, through the Beebe
Medical Group, Beebe Healthcare operates four walk-in centers and
over 20 physician practices representing over 40 specialties.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company
focused on commercializing the Aquadex FlexFlow System for
aquapheresis therapy. The Aquadex FlexFlow system is indicated for
temporary (up to eight hours) ultrafiltration treatment of patients
with fluid overload who have failed diuretic therapy and extended
(longer than 8 hours) ultrafiltration treatment of patients with
fluid overload who have failed diuretic therapy and require
hospitalization. All treatments must be administered by a
healthcare provider, under physician prescription, both of whom
have received training in extracorporeal therapies. The company's
mission is to predict, measure, and control patient fluid balance
through science, collaboration, and innovative medical technology.
CHF Solutions is a Delaware corporation headquartered in
Minneapolis, Minnesota with wholly owned subsidiaries in Australia
and Ireland. The company has been listed on the Nasdaq Capital
Market since February 2012.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements relating to potential uses for aquapheresis
and the Aquadex FlexFlow System. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risk associated with our ability to execute on
our commercial strategy, the possibility that we may be unable to
raise sufficient funds necessary for our anticipated operations,
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
our ability to integrate acquired businesses, our expectations
regarding anticipated synergies with and benefits from acquired
businesses, and other risks and uncertainties described in our
filings with the SEC. Forward-looking statements speak only as of
the date when made. CHF Solutions does not assume any obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
CONTACTS:
INVESTORS:Claudia Napal DraytonChief Financial
Officer CHF Solutions, Inc.952-345-4205ir@chf-solutions.com
-or-Bret Shapiro Managing Partner CORE
IR516-222-2560brets@coreir.com www.coreir.com
MEDIAJules AbrahamJQA Partners, Inc.
917-885-7378jabraham@jqapartners.comSource: CHF Solutions,
Inc.
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024